Company intelligence / Profile preview

Nutromics

Melbourne, Victoria, Australianutromics.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Nutromics has developed a wearable "lab-on-a-patch" device that uses microneedles coated with DNA-based sensors to provide real-time, continuous measurement of multiple biomarkers. The company completed a world-first safety study of its DNA sensor technology in humans in late 2023. Clinical validation and regulatory approval processes are ongoing; no commercial products have been launched yet.

Therapeutic areas: EndocrinologyNephrologyInfectious Diseases
Modalities: DeviceDNA-based biosensor platform (DNA sensor)Microneedle patch technology
Industry: Physiological Monitoring

Drug pipeline

1 asset

vancomycin

Pre-clinical

Indications: Infection

Partnerships

Academic collaborations with Monash University for clinical trialsStrategic investors include Dexcom Ventures

Beyond the preview

Go deeper on Nutromics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nutromics.

Explore the full profile